<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037409</url>
  </required_header>
  <id_info>
    <org_study_id>C0251005</org_study_id>
    <nct_id>NCT05037409</nct_id>
  </id_info>
  <brief_title>Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, DOUBLE BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETICS FOLLOWING SINGLE INTRAVENOUS DOSE OF PF-06823859 IN JAPANESE HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is to evaluate the safety, tolerability, immunogenicity and&#xD;
      pharmacokinetics (PK) of PF-06823859 following a single intravenous dose of PF-06823859 300&#xD;
      and 900 mg in Japanese healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 12 participants are planned to be enrolled into the study. The study consists&#xD;
      of 2 cohorts, and approximately 5 participants will be randomized to PF-06823859 and&#xD;
      approximately 1 participant will be randomized to placebo in each cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2021</start_date>
  <completion_date type="Anticipated">March 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 27, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessments of AEs/SAEs including infusion related reactions, infusion sites and viral infections</measure>
    <time_frame>Day 1-157</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessments of ECG QT interval</measure>
    <time_frame>Day 1-157</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessments of ECG QTc interval</measure>
    <time_frame>Day 1-157</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessments of ECG PR interval</measure>
    <time_frame>Day 1-157</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessments of ECG QRS interval</measure>
    <time_frame>Day 1-157</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessments of ECG heart rate</measure>
    <time_frame>Day 1-157</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessments of laboratory tests</measure>
    <time_frame>Day 1-157</time_frame>
    <description>Hemoglobin, Hematocrit, RBC count, MCV, MCH, MCHC, Platelet count, WBC count, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes, BUN and creatinine, Fasting glucose, Calcium, Sodium, Potassium, Chloride, AST, ALT, Total bilirubin, Alkaline phosphatase, Uric acid, Albumin, Total protein, pH, Glucose, Protein, Blood, Ketones, Nitrites, Leukocyte esterase, Urobilinogen, Urine bilirubin, Microscopy, PT, INR, aPTT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessments of supine blood pressure in mmHg</measure>
    <time_frame>Day 1-157</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessments of pulse rate in bpm</measure>
    <time_frame>Day 1-157</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose normalized Cmax</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which Cmax occurs (Tmax)</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time profile from time 0 extrapolated to infinite time (AUCinf)</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose normalized AUCinf</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast)</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose normalized AUClast</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time profile from time 0 to 14 days post-dose (AUC14day)</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time profile from time 0 to 28 days post-dose (AUC28day)</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the development of antidrug antibodies (ADA)</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the development of neutralizing antibodies (NAb)</measure>
    <time_frame>Day 1-157</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PF-06823859 low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single intravenous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06823859 high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single intravenous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive single intravenous infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06823859</intervention_name>
    <description>low dose or high dose intravenous infusion</description>
    <arm_group_label>PF-06823859 high</arm_group_label>
    <arm_group_label>PF-06823859 low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female participants must be 20 to 55 years of age, inclusive, at the time of&#xD;
             signing the Informed Consent Document (ICD).&#xD;
&#xD;
          2. Participants must have 4 biologically Japanese grandparents born in Japan.&#xD;
&#xD;
          3. Male and female participants who are overtly healthy as determined by medical&#xD;
             evaluation including medical history, physical examination, laboratory tests, and 12&#xD;
             lead electrocardiogram (ECG).&#xD;
&#xD;
          4. Participants who are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations, and other study procedures.&#xD;
&#xD;
          5. Body Mass Index (BMI) of 17.5 to 25 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
             Informed Consent:&#xD;
&#xD;
          6. Capable of giving signed informed consent as described in Appendix 1, which includes&#xD;
             compliance with the requirements and restrictions listed in the ICD and in this&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or&#xD;
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,&#xD;
             seasonal allergies at the time of dosing).&#xD;
&#xD;
          2. History of human immunodeficiency virus (HIV) infection, hepatitis C or syphilis;&#xD;
             positive testing for HIV, hepatitis C antibody (HCVAb) or syphilis at screening.&#xD;
&#xD;
          3. Infection with hepatitis b virus (HBV)&#xD;
&#xD;
          4. Clinically significant abnormality, including but not limited to current, active&#xD;
             tuberculosis (TB) or previous inactive TB, general infections, heart failure or&#xD;
             malignancy, on chest X ray performed at screening or within 12 weeks of screening.&#xD;
&#xD;
          5. History of autoimmune disorders.&#xD;
&#xD;
          6. History of allergic or anaphylactic reaction to a therapeutic drug or any components&#xD;
             in the study intervention.&#xD;
&#xD;
          7. Participants with clinically significant infections, based on which the investigator&#xD;
             judges that the participant should not be enrolled in the study, within 28 days prior&#xD;
             to the screening visit.&#xD;
&#xD;
          8. Participants with a fever, based on which the investigator judges that the participant&#xD;
             should not be enrolled in the study, within the last 7 days prior to dosing.&#xD;
&#xD;
          9. Participants who have evidence of tuberculosis infection.&#xD;
&#xD;
               -  Participants who have been treated or are currently being treated for active or&#xD;
                  latent tuberculosis infection are to be excluded.&#xD;
&#xD;
               -  Participants with a history of either untreated or inadequately treated latent or&#xD;
                  active tuberculosis infection are to be excluded.&#xD;
&#xD;
         10. Other medical or psychiatric condition including recent (within the past year) or&#xD;
             active suicidal ideation/behavior or laboratory abnormality or other conditions or&#xD;
             situations related to COVID-19 pandemic (eg, Contact with positive case, residence, or&#xD;
             travel to an area with high incidence) that may increase the risk of study&#xD;
             participation or, in the investigator's judgment, make the participant inappropriate&#xD;
             for the study.&#xD;
&#xD;
         11. Use of prescription or nonprescription drugs and dietary and herbal supplements within&#xD;
             7 days or 5 half lives (whichever is longer) prior to the first dose of study&#xD;
             intervention.&#xD;
&#xD;
         12. Recent exposure to any live or attenuated live virus vaccines within 6 weeks of&#xD;
             admission to central research unit (CRU)&#xD;
&#xD;
               -  The use of COVID-19 vaccines (except for live or attenuated live virus vaccines)&#xD;
                  are allowed before 14 days prior to Day 1 or after discharge from CRU.&#xD;
&#xD;
         13. Participants who have received PF-0 6823859 or any other interferon (IFN) alpha-or&#xD;
             IFN-beta therapy at any time in the past.&#xD;
&#xD;
         14. Previous administration with an investigational drug within 4 months (180 days for&#xD;
             biologics) or 5 half lives preceding the first dose of study intervention used in this&#xD;
             study (whichever is longer).&#xD;
&#xD;
         15. A positive urine drug test.&#xD;
&#xD;
         16. Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic),&#xD;
             following at least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm&#xD;
             Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP&#xD;
             values should be used to determine the participant's eligibility.&#xD;
&#xD;
         17. Screening pulse rate (PR) &gt;100 bpm. If the PR is greater than 100 beat per minute&#xD;
             (bpm), the PR should be repeated 2 more times and the average of the 3 PR values&#xD;
             should be used to determine the participant's eligibility.&#xD;
&#xD;
         18. Baseline standard 12 lead ECG that demonstrates clinically relevant abnormalities that&#xD;
             may affect participant safety or interpretation of study results.&#xD;
&#xD;
         19. Participants with ANY of the following abnormalities in clinical laboratory tests at&#xD;
             screening, as assessed by the study specific laboratory and confirmed by a single&#xD;
             repeat test, if deemed necessary:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)level ≥1.5 ×&#xD;
                  upper limit of normal (ULN);&#xD;
&#xD;
               -  Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's&#xD;
                  syndrome may have direct bilirubin measured and would be eligible for this study&#xD;
                  provided the direct bilirubin level is ≤ ULN.&#xD;
&#xD;
         20. A positive COVID-19 test by polymerase chain reaction (PCR) at screening.&#xD;
&#xD;
         21. History of alcohol abuse or binge drinking and/or any other illicit drug use or&#xD;
             dependence within 6 months of screening.&#xD;
&#xD;
         22. Blood donation (excluding plasma donations) of approximately ≥400 mL within 3 months&#xD;
             or ≥200 mL within a month prior to dosing. Additionally, approximately ≥400 mL within&#xD;
             4 months for female participants.&#xD;
&#xD;
         23. History of sensitivity to heparin or heparin induced thrombocytopenia only if heparin&#xD;
             is planned to flush intravenous catheters.&#xD;
&#xD;
         24. History of substance abuse within 12 months of the screening visit.&#xD;
&#xD;
         25. Pregnant females; breastfeeding females.&#xD;
&#xD;
         26. Unwilling or unable to comply with the criteria in the Lifestyle Considerations&#xD;
             section of this protocol.&#xD;
&#xD;
         27. Investigator site staff or Pfizer employees directly involved in the conduct of the&#xD;
             study, site staff otherwise supervised by the investigator, and their respective&#xD;
             family members.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Corporation Shinanokai Shinanozaka Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C0251005</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

